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Case report
The patient is a 27-year-old white man who received a
living-related donor transplant from his father at 11 years
of age in 1986 for end stage renal disease secondary to
posterior urethral valves. The patient was seronegative for
cytomegalovirus (CMV) and Epstein–Barr virus (EBV)
prior to transplantation. His father’s EBV and CMV sta-
tus were unavailable. The transplant course was complica-
ted by immediate postoperative acute renal artery
thrombosis, which required transplant nephrectomy. He
then received a deceased donor renal transplant 10 days
later. Maintenance immunosuppression consisted of
cyclosporine (Sandimmune formulation), azathioprine,
and prednisone. He received 12 doses of Minnesota
equine antilymphocyte immunoglobulin (MALG) for
induction followed by 10 doses of murine anti-CD3
monoclonal antibody (OKT3) for two episodes of acute
graft rejection over the 7 weeks following the transplant.
The deceased donor’s EBV and CMV status were unavail-
able from medical records. The patient developed acute
infectious mononucleosis 2 months after transplanta-
tion demonstrated by positive EBV serology. He was trea-
ted with acyclovir and the infectious mononucleosis
resolved.
At the age of 18, he presented with 5 months of fever,
weight-loss and night sweats, and was found to have axil-
lary adenopathy, splenomegaly and bulky right mediastinal
adenopathy. A right anterior, thoracotomy and lymph node
biopsy demonstrated Hodgkin’s disease, nodular sclerosing
subtype. Hodgkin’s–Reed–Sternberg (HRS) cells were
strongly positive for CD30 and EBV-latent membrane pro-
tein (LMP)-1. He was staged as Hodgkin’s disease-IIIB. His
EBV serology demonstrated elevated antiviral capsid anti-
gen (VCA) IgG titers and positive anti-VCA IgM, consis-
tent with reactivation of EBV infection.
He was given six cycles of adriamycin, bleomycin, vin-
blastine, and dacarbazine (ABVD) chemotherapy, without
signiﬁcant side effects, and his Hodgkin’s Disease went
into remission. His serum creatinine after therapy was
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Summary
Hodgkin’s disease is recognized as part of the spectrum of post-transplantation
lymphoproliferative disorders (PTLD), although it is still an uncommon
de novo malignancy in this population. Epstein–Barr virus (EBV) has been
linked to both post-transplant non-Hodgkin’s lymphomas and Hodgkin’s dis-
ease. We report a case of recurrent Hodgkin’s disease in a patient who received
a renal transplant in childhood and later developed EBV-associated Hodgkin’s
disease with remission after chemotherapy until subsequent relapse 9 years later
that was successfully treated. To our knowledge, this is the ﬁrst report of recur-
rent Hodgkin’s disease in a transplant recipient. We brieﬂy discuss the patho-
genesis of and risk factors for EBV-related PTLD, utility of EBV load
surveillance, and the options for treatment of PTLD including immunosup-
pression reduction, antiviral therapy, anti-CD20 monoclonal antibodies, cyto-
toxic T cells, and the possible roles of interferon-a and rapamycin.
Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit commercial
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and cyclosporine and prednisone continued until he
developed renal insufﬁciency, with a serum creatinine of
7.8 mg/dl 5-years later. A biopsy showed severe chronic
rejection. The patient was changed from Sandimmune to
Neoral, and mycophenolate mofetil (MMF) was added.
Notably, his CMV IgG and IgM were positive at this time,
indicating seroconversion in the preceding 2 years since his
CMV status had last been determined. His renal function
improved to his baseline serum creatinine of 2.4 mg/dl.
Four years later, serum creatinine was 3.2 mg/dl and a
biopsy demonstrated chronic allograft nephropathy with
moderate interstitial ﬁbrosis. Neoral was changed to tacro-
limus, and he continued on MMF and prednisone. His
creatinine stabilized at a new baseline of 2.7 mg/dl.
Nine years after remission, the patient was found to
have hypercalcemia of 15.4 mg/dl associated only with
irritability. He was found to have retroaortic and retroc-
rural lymphadenopathy with mild paratracheal lympha-
denopathy on Computed Tomography scan. Excisional
biopsy showed Hodgkin’s disease-IIIA of mixed cellularity
subtype. The HRS cells were strongly positive for CD15,
CD30, and EBV LMP-1. The patient’s serology showed
elevated anti-VCA IgM and anti-VCA IgG titers.
Tacrolimus and MMF were discontinued, and ABVD
and valganciclovir commenced. He achieved remission
of his recurrent HD with chemotherapy and immunosup-
pressive withdrawal. Adriamycin was subsequently changed
to doxorubicin to prevent cardiotoxicity, and bleomycin
was discontinued from his regimen secondary to lung tox-
icity. His chronic renal insufﬁciency worsened, and he
returned to hemodialysis 9 months after diagnosis of recur-
rent Hodgkin’s Disease. At the time of his return to dialysis,
he was found to have a positive hepatitis C antibody.
Discussion
Although several case reports of Hodgkin’s disease and
Hodgkin-like PTLD (HL-PLTD) after organ transplanta-
tion have been published, no case of recurrent classic
Hodgkin’s disease has yet been reported [1]. Our patient
is remarkable for late recurrent Hodgkin’s disease after
renal transplantation in association with reactivation of
EBV infection, similar to his initial episode.
Epstein–Barr virus genomes have been detected in 60%
of Hodgkin’s disease in immunocompetent individuals,
and EBV viremia is common with infectious mononucle-
osis [2]. Expression of EBV-encoded proteins in HRS is
limited to the latency II pattern with EBNA1, LMP-1, 2A,
2B proteins, and EBV early RNAs (EBERS) [3]. The most
important of the EBV genome products is an LMP-1 pro-
tein, which is highly expressed in HRS cells in EBV-associ-
ated Hodgkin’s disease.
Latent membrane protein (LMP)-1 is an integral mem-
brane protein that mimics a constitutively active CD40
receptor on B cells [4]. The LMP-1 is a target epitope for
cytotoxic T cell recognition for EBV-infected cells, and
transplant patients are unable to recognize and destroy
these cells because of immunosuppression. Certain immu-
nosuppressants increase the likelihood of PTLD by the
suppression of cytotoxic T cell surveillance.
Other risk factors for the development of PTLD
include intensity of immunosuppression, EBV seronega-
tive status, young age, induction therapy with antilym-
phocyte agents such as OKT3, and infection with CMV
or hepatitis C [5, 6]. Our patient received OKT3 prior to
his ﬁrst episode of Hodgkin’s disease, had been treated
with tacrolimus for several years before recurrence of
Hodgkin’s disease, and had become CMV and hepatitis C
seropositive in the interval between his ﬁrst and second
episodes of Hodgkin’s disease.
Monitoring EBV loads may allow for detection of early
PTLD, but the utility of following EBV viral loads is
unclear. Assays are not standardized, and it is not known
which tissue to sample, or when to test [7]. In pediatric
organ transplant recipients, high viral loads are sensitive
but not speciﬁc for the development of PTLD. In adults,
high EBV levels are not sensitive but are speciﬁc for the
development of PTLD. EBV-associated PTLD has been
demonstrated in patients with low or undetectable EBV
loads, and elevated EBV viral loads develop in patients with
EBV-associated viral syndromes [8]. Monitoring viral loads
during the treatment of EBV may aid management. Persist-
ently elevated titers necessitate alternative treatment.
A novel method for detection of EBV-mediated trans-
formation of B-cells was recently described in which a
spontaneous EBV B-cell transformation assay (SET) was
used to monitor an EBV-speciﬁc immunity in vivo.A
positive SET correlated with a decrease in EBV-peptide-
speciﬁc CD8+ T cells and a higher rate of EBV replication
and B-cell transformation in the absence of cytotoxic
T-cell suppression. Reduction of immunosuppression
resulted in negative SET assays, and this approach may
allow for surveillance of EBV-mediated lymphoprolifera-
tion in transplant patients [9].
Treatment of PTLD includes reduction of immunosup-
pression, antiviral therapy, anti-CD20 monoclonal anti-
bodies, intravenous immunoglobulin (IVIG), cytotoxic T
cells, radiation and surgery. Reduction of immuno-
suppression is ﬁrst-line therapy and enables native
immune function to clear the EBV-viremia and associated
PTLD [10].
The utility of antivirals for treatment is unclear. Most
EBV-infected cells within PTLD lesions are in the latent
phase of replication, and antivirals such as acyclovir and
ganciclovir target the lytic phase. There is an increasing
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role in PTLD than previously thought [7].
The use of anti-B cell monoclonal antibodies is increas-
ing. In a recent retrospective study of 30 solid organ
transplant patients with PTLD at the Mayo Clinic, 15
CD20 and EBER-positive patients who did not respond
to reduction of immunosuppression were treated with
rituximab [11]. Rituximab was associated with a signiﬁ-
cantly improved survival by multivariate analysis.
Complications included profound hypogammaglobuline-
mia, CMV reactivation with intestinal perforation,
hepatitis B and C reactivation, and parvovirus-induced
red blood cell aplasia [7].
Therapy with cytotoxic T cells for prevention and treat-
ment of EBV-related PTLD has been investigated in solid
organ transplant and bone marrow transplant (BMT)
patients. Comoli et al. [12] developed autologous EBV-
speciﬁc CTLs for 23 patients at high risk for PTLD
because of elevated EBV DNA loads. Seven patients
received EBV-speciﬁc CTLs and a stable decrease in EBV
load was detected in ﬁve without graft function compro-
mise, and in a 30-month follow-up no patients developed
PTLD, even in the two patients who did not respond.
Interferon-a and rapamycin have also been used in
treatment of PTLD. The potential for eliciting acute
allograft rejection with interferon-a limits its use [1].
Rapamycin, a transplant immunosuppressant, has
antiproliferative activity against EBV-associated PTLD
in vitro, and inhibits the growth of solid tumors from
EBV-infected B cell lines in a xenogeneic mouse model of
PTLD [13]. Rapamycin may therefore be useful for both
immunosuppression and treatment of EBV-associated
PTLD but more data are needed.
Prophylaxis for PTLD with antivirals has been used.
Despite a greater degree of immunosuppression in the
ganciclovir group, prophylaxis with ganciclovir was more
effective than acyclovir in a high-risk group of 198
patients, with solid organ transplants, who received OKT3
induction therapy. PTLD developed in 0.5% in the ganci-
clovir group and 3.9% in the acyclovir group [14]. Pro-
phylaxis with ganciclovir may have been more effective,
indirectly, as it is more effective than acyclovir against
CMV.
In summary, we report the ﬁrst case of recurrent
Hodgkin’s disease in a renal transplant patient with
numerous risk factors for PTLD. Our case is notable for
several features: (i) initial EBV seronegativity, (ii) subse-
quent conversion after an acute infectious mononucleosis
infection early after transplantation, (iii) the subsequent
development of Hodgkin’s disease with successful treat-
ment, (iv) and then recurrent Hodgkin’s disease success-
fully treated. Both instances of Hodgkin’s disease were
associated with reactivation of EBV. Further investigation
of the complex mechanisms promoting the EBV transfor-
mation of B cells in immunocompromised hosts is
necessary, and options for treatment of PTLD continue to
broaden.
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